momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (2230)	8/20/2005 3:25:01 AM
From: tuck	Read Replies (3) of 12215

Signals has a recent article on the subject of Toll-like receptors, and identifies other players, as well as offering a primer on the science: signalsmag.com Note that Hybridon's partnered program goes after asthma and allergy, which Rick alluded to as more likely diseases to target by this path. Unfortunately, they currently have their cancer program to themselves. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next